A Phase 1 interventional study of TAS-102 in Advanced or Metastatic Solid Tumors, sponsored by Taiho Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-14.
Sponsored by Taiho Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the pharmacokinetics of TAS-102 after single and multiple dose in Chinese patients with solid tumor.
This is an open-label, non-randomized, single group Phase 1 study of TAS-102, evaluating the pharmacokinetics, safety, and antitumor activity. Blood sampling will be performed during the first cycle (Day1 and Day 12) of therapy in all consenting patients.
Taiho Pharmaceutical Co., Ltd. is the lead sponsor of 43 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TAS-102
TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Cmax (Maximum Plasma Concentration) of FTD
Time frame: Multiple time points on Day 1 and Day 12 of Cycle 1.
Tmax (Time to Reach Maximum Drug Concentration in Blood) of FTD
Time frame: Multiple time points on Day 1 and Day 12 of Cycle 1.
AUC0-t (Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time (t) of the Last Quantifiable Concentration ) of FTD
Time frame: Multiple time points on Day 1 and Day 12 of Cycle 1.
| Milestone | TAS-102 |
|---|---|
| Started | 15 |
| Completed | 15 |
| Not completed | 0 |
| ng/mL | TAS-102 |
|---|---|
| Day 1 | 3019.49 ± 34.0 |
| Day 12 | 3693.08 ± 21.7 |
| hours | TAS-102 |
|---|---|
| Day 1 | 1.00 ± 58.7 |
| Day 12 | 2.61 ± 36.2 |
| ng·hr/mL | TAS-102 |
|---|---|
| Day 1 | 7796.60 ± 19.1 |
| Day 12 | 18181.34 ± 30.0 |
Collected over 15 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TAS-102 | 0/15 (0%) | 4/15 (26.7%) | 14/15 (93.3%) |
| Event | TAS-102 |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/15 |
| NauseaGastrointestinal disorders | 1/15 |
| Small intestinal obstructionGastrointestinal disorders | 1/15 |
| VomitingGastrointestinal disorders | 1/15 |
| FatigueGeneral disorders | 1/15 |
| Platelet count decreasedInvestigations | 1/15 |
| Bone painMusculoskeletal and connective tissue disorders | 1/15 |
| DizzinessNervous system disorders | 1/15 |
| HeadacheNervous system disorders | 1/15 |
| Event | TAS-102 |
|---|---|
| NauseaGastrointestinal disorders | 12/15 |
| VomitingGastrointestinal disorders | 9/15 |
| FatigueGeneral disorders | 7/15 |
| Decreased appetiteMetabolism and nutrition disorders | 7/15 |
| ConstipationGastrointestinal disorders | 5/15 |
| LeukopeniaBlood and lymphatic system disorders | 5/15 |
| NeutropeniaBlood and lymphatic system disorders | 5/15 |
| Neutrophil count decreasedInvestigations | 4/15 |
| White blood cell count decreasedInvestigations | 4/15 |
| DiarrhoeaGastrointestinal disorders | 3/15 |
| Age, Continuous(years) | TAS-102 |
|---|---|
| Median | 56.0 (35 to 64) |
| Sex: Female, Male(Participants) | TAS-102 |
|---|---|
| Female | 3 |
| Male | 12 |
| Region of Enrollment(participants) | TAS-102 |
|---|---|
| China | 15 |
Ran from Sep 2014 to primary completion in Oct 2015, 13 months.
Results were first posted in Oct 2024, 9 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taiho Pharmaceutical Co., Ltd. →